

# Masanori Koide

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5511973/publications.pdf>

Version: 2024-02-01

32  
papers

1,431  
citations

430874

18  
h-index

414414

32  
g-index

32  
all docs

32  
docs citations

32  
times ranked

1904  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibitor of protein kinase N3 suppresses excessive bone resorption in ovariectomized mice. <i>Journal of Bone and Mineral Metabolism</i> , 2022, 40, 251-261.	2.7	1
2	Evidence for the major contribution of remodeling-based bone formation in sclerostin-deficient mice. <i>Bone</i> , 2022, 160, 116401.	2.9	5
3	Angiotensin II Induces Aortic Rupture and Dissection in Osteoprotegerin-Deficient Mice. <i>Journal of the American Heart Association</i> , 2022, 11, e025336.	3.7	7
4	Positive and Negative Regulators of Sclerostin Expression. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4895.	4.1	7
5	Osteoclast differentiation by RANKL and OPG signaling pathways. <i>Journal of Bone and Mineral Metabolism</i> , 2021, 39, 19-26.	2.7	293
6	Sclerostin expression in trabecular bone is downregulated by osteoclasts. <i>Scientific Reports</i> , 2020, 10, 13751.	3.3	17
7	Blockade of the angiotensin II type 1 receptor increases bone mineral density and left ventricular contractility in a mouse model of juvenile Paget disease. <i>European Journal of Pharmacology</i> , 2019, 859, 172519.	3.5	3
8	The Regulation of Bone Metabolism and Disorders by Wnt Signaling. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5525.	4.1	214
9	Regulatory mechanisms of sclerostin expression during bone remodeling. <i>Journal of Bone and Mineral Metabolism</i> , 2019, 37, 9-17.	2.7	32
10	Effects of shokyo ( <i>Zingiberis Rhizoma</i> ) and kankyo ( <i>Zingiberis Processum Rhizoma</i> ) on prostaglandin E <sub>2</sub> production in lipopolysaccharide-treated mouse macrophage RAW264.7 cells. <i>PeerJ</i> , 2019, 7, e7725.	2.0	1
11	Bone Formation Is Coupled to Resorption Via Suppression of Sclerostin Expression by Osteoclasts. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 2074-2086.	2.8	55
12	The W9 peptide directly stimulates osteoblast differentiation via RANKL signaling. <i>Journal of Oral Biosciences</i> , 2017, 59, 146-151.	2.2	6
13	A Jak1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro. <i>PLoS ONE</i> , 2017, 12, e0181126.	2.5	68
14	Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis. <i>PLoS ONE</i> , 2017, 12, e0184904.	2.5	31
15	Wnt16 regulates osteoclast differentiation in conjunction with Wnt5a. <i>Biochemical and Biophysical Research Communications</i> , 2015, 463, 1278-1283.	2.1	39
16	The regulation of osteoclast differentiation by Wnt signals. <i>BoneKey Reports</i> , 2015, 4, 713.	2.7	47
17	Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma. <i>Journal of Neurosurgery</i> , 2015, 123, 989-997.	1.6	74
18	Roles of cathelicidin-related antimicrobial peptide in murine osteoclastogenesis. <i>Immunology</i> , 2013, 140, 344-351.	4.4	28

#	ARTICLE	IF	CITATIONS
19	Minocycline to be used a potential anti-bone resorption agents due to the suppression of osteoclastic bone resorption. <i>Journal of Oral Biosciences</i> , 2013, 55, 16-22.	2.2	7
20	Osteoprotegerin-Deficient Male Mice as a Model for Severe Alveolar Bone Loss: Comparison With RANKL-Overexpressing Transgenic Male Mice. <i>Endocrinology</i> , 2013, 154, 773-782.	2.8	48
21	Tetracyclines Convert the Osteoclastic-Differentiation Pathway of Progenitor Cells To Produce Dendritic Cell-like Cells. <i>Journal of Immunology</i> , 2012, 188, 1772-1781.	0.8	36
22	Prostaglandin E2 receptor EP4-selective agonist (ONO-4819) increases bone formation by modulating mesenchymal cell differentiation. <i>European Journal of Pharmacology</i> , 2011, 650, 396-402.	3.5	20
23	Osteoclastic bone resorption induced by innate immune responses. <i>Periodontology 2000</i> , 2010, 54, 235-246.	13.4	46
24	IL-12 stimulates the osteoclast inhibitory peptide-1 (OIP-1/hSca) gene expression in CD4+ T cells. <i>Journal of Cellular Biochemistry</i> , 2009, 107, 104-111.	2.6	11
25	Evaluation of Pharmaceuticals With a Novel 50-Hour Animal Model of Bone Loss. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 1194-1205.	2.8	103
26	Diphenylhydantoin Inhibits Osteoclast Differentiation and Function Through Suppression of NFATc1 Signaling. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 1469-1480.	2.8	36
27	The relationship between calcium accumulation in osteoclast mitochondrial granules and bone resorption. <i>Bone</i> , 2009, 45, 980-986.	2.9	18
28	Lipopolysaccharide-Mediated Enhancement of Bone Metabolism in Estrogen-Deficient Mice. <i>Journal of Periodontology</i> , 2008, 79, 2173-2181.	3.4	1
29	Actinobacillus actinomycetemcomitans Y4 capsular polysaccharide induces IL-1beta mRNA expression through the JNK pathway in differentiated THP-1 cells. <i>Clinical and Experimental Immunology</i> , 2005, 141, 261-269.	2.6	11
30	Cytokine Regulation and the Signaling Mechanism of Osteoclast Inhibitory Peptide-1 (OIP-1/hSca) to Inhibit Osteoclast Formation. <i>Journal of Bone and Mineral Research</i> , 2003, 18, 458-465.	2.8	22
31	Identification of the Functional Domain of Osteoclast Inhibitory Peptide-1/hSca. <i>Journal of Bone and Mineral Research</i> , 2002, 17, 111-118.	2.8	10
32	Gingival crevicular interleukin-1 and interleukin-1 receptor antagonist levels in periodontally healthy and diseased sites. <i>Journal of Periodontal Research</i> , 1997, 32, 524-529.	2.7	134